New DNA-HPV Test Reaches 26 States in SUS for Cervical Cancer Prevention

Following the nationwide adoption of molecular screening in public health clinics, Brazil’s Unified Health System (SUS) detected 9,904 positive results for high-risk human papillomavirus (HPV) subtypes associated with cervical cancer. The transition from traditional cytopathology to automated molecular testing marks a major shift in the country’s oncological prevention strategy.

In Plain English: The Clinical Takeaway

• Molecular Screening: The SUS replaced the traditional Papanicolau (Pap smear) test with a DNA-HPV test in 26 states, utilizing a polymerase chain reaction (PCR) mechanism to detect viral DNA before cellular changes occur.
• High-Risk Subtypes: The 9,904 positive tests specifically isolate high-risk oncogenic strains of HPV known to drive cervical carcinogenesis.
• Early Detection Window: Clinical data from a University of Campinas (Unicamp) study in Indaiatuba demonstrated that molecular screening anticipates cervical cancer detection by a decade compared to conventional cytology.

Nationwide Implementation and Screening Metrics

The molecular DNA-HPV initiative has processed 93,000 samples throughout 2026, contributing to a total of 153,000 samples collected since the protocol's inception, according to data released by the Ministry of Health. The screening infrastructure spans 26 federal units, with collection protocols executed by primary care professionals across basic health units (UBS). Boa Vista announced the local rollout of the diagnostic tool to modernize early detection pathways.

The diagnostic shift alters clinical intervals for patients who test negative. According to government public health documentation, a negative DNA-HPV result permits a safe five-year screening interval before subsequent collection, optimizing laboratory throughput and minimizing unsatisfactory sample rates.

Screening Parameter	Traditional Papanicolau Test	SUS DNA-HPV Molecular Test
Target Analyte	Morphological cellular abnormalities	Viral oncogenic DNA sequences
Mean Detection Age	49.3 years	39.6 years
National Processing Volume	Not specified	93,000 samples processed in 2026

Epidemiological Risk Factors and Diagnostic Projections

Cervical cancer represents the third most frequently diagnosed malignancy among women in Brazil. Projections from the Brazilian National Cancer Institute (INCA) estimate that the country could register approximately 19,300 new cases of cervical cancer per year between 2026 and 2028. Clinical data emphasizes that timely diagnosis yields survival rates exceeding 95%, with government figures noting that with timely diagnosis, the chances of cure are 100%.

Photo: GOV.BR

Vulnerability factors significantly influence tumor incidence. Populations experiencing social vulnerability, low educational attainment, and individuals living with HIV face elevated risks—with HIV-positive patients exhibiting up to a fivefold higher probability of developing oncogenic lesions.

Contraindications & When to Consult a Doctor

Warning signs requiring diagnostic investigation include intermenstrual bleeding, postcoital bleeding, bleeding following menopause, atypical vaginal discharge accompanied by odor or blood, and pelvic or lower back discomfort.

Photo: G1

Complementary prevention relies heavily on immunization. Brazil’s public health immunization framework provides free vaccination for children and adolescents aged 9 to 14, achieving coverage rates of 87% among girls and 74% among boys in 2025. Additional immunization access covers oncological patients, victims of sexual violence aged 9 to 45, and immunosuppressed individuals, including transplant recipients and persons living with HIV or AIDS.

References

• Ministério da Saúde. Teste para detecção precoce do câncer do colo do útero já está disponível em 26 estados do país.
• Instituto Nacional de Câncer (INCA). Câncer do colo do útero: Informações e Diretrizes de Rastreamento.
• VEJA. HPV: os primeiros números do novo teste para prevenção do câncer de colo do útero no SUS.
• Agência Brasil. SUS detecta quase 10 mil testes positivos para HPV de alto risco.